Clinical Case Discussion: An Adult Patient with Uncontrolled Moderate-to-Severe Atopic Dermatitis and a Treatment Option for Appropriate Patients 6+ Months of Age<br> <span style="color: #009B77">by Andrew Baker, PA-C</span> Oct 6 Clinical Case Discussion: An Adult Patient with Uncontrolled Moderate-to-Severe Atopic Dermatitis and a Treatment Option for Appropriate Patients 6+ Months of Age by Andrew Baker, PA-C 12:15 pm - 1:15 pm
The Many Faces of Type 2 Inflammation: Unraveling Its Role Across Dermatologic Conditions and a Treatment Option for Appropriate Patients <br> <span style="color: #009B77">by Justin Love, PA-C</span> Oct 7 The Many Faces of Type 2 Inflammation: Unraveling Its Role Across Dermatologic Conditions and a Treatment Option for Appropriate Patients by Justin Love, PA-C 12:15 pm - 1:15 pm
A Treatment Option for Appropriate Patients with Certain Skin Diseases Driven in Part by Type 2 Inflammation<br> <span style="color: #009B77">by Gina Mangin, PA-C</span> Oct 8 A Treatment Option for Appropriate Patients with Certain Skin Diseases Driven in Part by Type 2 Inflammation by Gina Mangin, PA-C 12:15 pm - 12:45 pm
Exploring the Pathophysiology of Type 2 Inflammation in Chronic Spontaneous Urticaria (CSU) and a Treatment Option for Appropriate CSU Patients 12+ Years of Age<br> <span style="color: #009B77">by Cynthia Trickett, PA-C</span> Oct 9 Exploring the Pathophysiology of Type 2 Inflammation in Chronic Spontaneous Urticaria (CSU) and a Treatment Option for Appropriate CSU Patients 12+ Years of Age by Cynthia Trickett, PA-C 12:15 pm - 1:15 pm
DUPIXENT<sup>@</sup> (dupilumab) Pediatric Caregiver Story followed by A Treatment Option for Appropriate Patients with Certain Skin Diseases Driven in Part by Type 2 Inflammation<br> <span style="color: #009B77">by Lisa Swanson, MD</span> Oct 14 DUPIXENT@ (dupilumab) Pediatric Caregiver Story followed by A Treatment Option for Appropriate Patients with Certain Skin Diseases Driven in Part by Type 2 Inflammation by Lisa Swanson, MD 12:15 pm - 1:15 pm
Beneath the Itch: The Role of Type 2 Inflammation and a Treatment Option for Appropriate Patients with Certain Skin Diseases Driven in Part by Type 2 Inflammation<br> <span style="color: #009B77">by Ty Hanson, DO</span> Oct 15 Beneath the Itch: The Role of Type 2 Inflammation and a Treatment Option for Appropriate Patients with Certain Skin Diseases Driven in Part by Type 2 Inflammation by Ty Hanson, DO 12:15 pm - 1:15 pm
Pearls and Common Challenges for the Diagnosis of Bullous Pemphigoid (BP) <br> <span style="color: #009B77;">by Matthew Lewis, MD</span> Oct 15 Pearls and Common Challenges for the Diagnosis of Bullous Pemphigoid (BP) by Matthew Lewis, MD 12:15 pm - 1:15 pm
Clinical Case Discussion: An Adult Patient with Prurigo Nodularis and a Treatment Option for Appropriate Patients 18+ Years of Age<br> <span style="color: #009B77;">by Michael Payette, MD</span> Oct 16 Clinical Case Discussion: An Adult Patient with Prurigo Nodularis and a Treatment Option for Appropriate Patients 18+ Years of Age by Michael Payette, MD 12:15 pm - 1:15 pm
Clinical Case Discussion: A Pediatric Patient with Uncontrolled Moderate-to-Severe Atopic Dermatitis and a Treatment Option for Appropriate Patients 6+ Months of Age <br> <span style="color: #009B77;">by Dareen Siri, MD</span> Oct 16 Clinical Case Discussion: A Pediatric Patient with Uncontrolled Moderate-to-Severe Atopic Dermatitis and a Treatment Option for Appropriate Patients 6+ Months of Age by Dareen Siri, MD 12:15 pm - 1:15 pm
DUPIXENT<Sup>®</sup> (dupilumab) Pediatric Caregiver Story followed by A Treatment Option for Appropriate Patients with Certain Skin Diseases Driven in Part by Type 2 Inflammation<br> <span style="color: #009B77;">by Dareen Siri, MD</span> Oct 20 DUPIXENT® (dupilumab) Pediatric Caregiver Story followed by A Treatment Option for Appropriate Patients with Certain Skin Diseases Driven in Part by Type 2 Inflammation by Dareen Siri, MD 12:15 pm - 1:15 pm
